Last reviewed · How we verify

NCT01767415

Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection

Completed Phase 1/Phase 2 Results posted Last updated 26 November 2018
What this trial tests

Phase 1/Phase 2 trial testing Indigo carmine in Brain Tumors With Ill-defined Margins in 10 participants. Completed in 1 September 2014.

Timeline
1 April 2012
Primary endpoint
1 April 2014
1 September 2014

Quick facts

Lead sponsorWeill Medical College of Cornell University
PhasePhase 1/Phase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment10
Start date1 April 2012
Primary completion1 April 2014
Estimated completion1 September 2014
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Weill Medical College of Cornell University

Who can join

Adults 18 to 65, any sex, with Brain Tumors With Ill-defined Margins. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to investigate whether stereotactic indigo carmine injection can safely increase the extent of tumor resection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Indigo carmine

Trials testing the same drug.

Other Weill Medical College of Cornell University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01767415.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing